Dr. DeLiberty successfully defended his thesis, “Therapeutic Targeting of RAS-Driven Metabolic Dependencies by PIKfyve Inhibition,” under the guidance of Drs. Kirsten Bryant and Channing Der.
Publications
Functional and biological heterogeneity of KRASQ61 mutations. Huynh MV, Hobbs GA, Schaefer A, Pierobon M, Carey LM, Diehl JN, DeLiberty JM, Thurman RD, Cooke AR, Goodwin CM, Cook JH, Lin L, Waters AM, Rashid NU, Petricoin EF 3rd, Campbell SL, Haigis KM, Simeone DM, Lyssiotis CA, Cox AD, Der CJ. Sci Signal. 2022 Aug 9; 15(746):eabn2694. doi: 10.1126/scisignal.abn2694. Epub 2022 Aug 9. PMID: 35944066
Unraveling and targeting RAS-driven metabolic signaling for therapeutic gain. DeLiberty JM, Robb R, Gates CE, Bryant KL. Adv Cancer Res. 2022; 153:267-304. doi: 10.1016/bs.acr.2021.07.010. Epub 2021 Aug 26. PMID: 35101233 Review.
Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors. Stalnecker CA, Grover KR, Edwards AC, Coleman MF, Yang R, DeLiberty JM, Papke B, Goodwin CM, Pierobon M, Petricoin EF, Gautam P, Wennerberg K, Cox AD, Der CJ, Hursting SD, Bryant KL.Cancer Res. 2022 Feb 15; 82(4):586-598. doi: 10.1158/0008-5472.CAN-21-1443. PMID: 34921013
CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Klomp JE, Lee YS, Goodwin CM, Papke B, Klomp JA, Waters AM, Stalnecker CA, DeLiberty JM, Drizyte-Miller K, Yang R, Diehl JN, Yin HH, Pierobon M, Baldelli E, Ryan MB, Li S, Peterson J, Smith AR, Neal JT, McCormick AK, Kuo CJ, Counter CM, Petricoin EF 3rd, Cox AD, Bryant KL, Der CJ. Cell Rep. 2021 Nov 30; 37(9):110060. doi: 10.1016/j.celrep.2021.110060. PMID: 34852220
Non-steroidal anti-inflammatory drugs induce immunogenic cell death in suppressing colorectal tumorigenesis. Fletcher R, Tong J, Risnik D, Leibowitz BJ, Wang YJ, Concha-Benavente F, DeLiberty JM, Stolz DB, Pai RK, Ferris RL, Schoen RE, Yu J, Zhang L. Oncogene. 2021 Mar; 40(11):2035-2050. doi: 10.1038/s41388-021-01687-8. Epub 2021 Feb 18. PMID: 33603166
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. Hobbs GA, Baker NM, Miermont AM, Thurman RD, Pierobon M, Tran TH, Anderson AO, Waters AM, Diehl JN, Papke B, Hodge RG, Klomp JE, Goodwin CM, DeLiberty JM, Wang J, Ng RWS, Gautam P, Bryant KL, Esposito D, Campbell SL, Petricoin EF 3rd, Simanshu DK, Aguirre AJ, Wolpin BM, Wennerberg K, Rudloff U, Cox AD, Der CJ. Cancer Discov. 2020 Jan; 10(1):104-123. doi: 10.1158/2159-8290.CD-19-1006. Epub 2019 Oct 24. PMID: 31649109
A first authored research paper has been accepted at Cancer Research journal.
Deliberty has accepted a Postdoctoral position at the Dana-Farber Cancer Institute, where he will be co-mentored by Joe Mancias and Andy Aguirre.
Honors, Awards & Highlights
American Association for Cancer Research (AACR) Scholar-in-Training Award, 2024
An award supported by Let’s Win Pancreatic Cancer that supported attending the AACR Special Conference in Advances in Pancreatic Cancer Research Boston, MA.
Best Oral Presentation, Pharmacology Retreat, 2023
Pharmacology Student Scholar, 2022
Second Place for Best Graduate, UNC Integrated Training in Cancer Model Systems, 2022
TIBBS ImPACT Scholar, UNC Training Initiatives in Biomedical and Biological Sciences, 2022
Award to support doing an internship during my graduate studies
Congratulations, Jonathan! We wish you all the best!
